335 related articles for article (PubMed ID: 33267867)
1. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
[TBL] [Abstract][Full Text] [Related]
2. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
[TBL] [Abstract][Full Text] [Related]
3. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.
Buas MF; Rho JH; Chai X; Zhang Y; Lampe PD; Li CI
Breast Cancer Res Treat; 2015 Sep; 153(2):445-54. PubMed ID: 26319120
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
[TBL] [Abstract][Full Text] [Related]
5. Breast invasive ductal carcinoma diagnosis with a three-miRNA panel in serum.
Chen X; Li X; Wang J; Zhao L; Peng X; Zhang C; Liu K; Huang G; Lai Y
Biomark Med; 2021 Aug; 15(12):951-963. PubMed ID: 34293926
[No Abstract] [Full Text] [Related]
6. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
[TBL] [Abstract][Full Text] [Related]
8. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
9. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
10. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
[TBL] [Abstract][Full Text] [Related]
11. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers.
Del Pilar Chantada-Vázquez M; López AC; Vence MG; Vázquez-Estévez S; Acea-Nebril B; Calatayud DG; Jardiel T; Bravo SB; Núñez C
J Proteomics; 2020 Feb; 212():103581. PubMed ID: 31731051
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.
Berg WA; Gutierrez L; NessAiver MS; Carter WB; Bhargavan M; Lewis RS; Ioffe OB
Radiology; 2004 Dec; 233(3):830-49. PubMed ID: 15486214
[TBL] [Abstract][Full Text] [Related]
13. CE-Magnetic Resonance Mammography for the evaluation of the contralateral breast in patients with diagnosed breast cancer.
Pediconi F; Venditti F; Padula S; Roselli A; Moriconi E; Giacomelli L; Catalano C; Passariello R
Radiol Med; 2005; 110(1-2):61-8. PubMed ID: 16163140
[TBL] [Abstract][Full Text] [Related]
14. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
15. Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach.
Kadowaki M; Sangai T; Nagashima T; Sakakibara M; Yoshitomi H; Takano S; Sogawa K; Umemura H; Fushimi K; Nakatani Y; Nomura F; Miyazaki M
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1105-15. PubMed ID: 21253761
[TBL] [Abstract][Full Text] [Related]
16. An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Mangé A; Dimitrakopoulos L; Soosaipillai A; Coopman P; Diamandis EP; Solassol J
J Proteomics; 2016 Jun; 142():114-21. PubMed ID: 27168011
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K; Masuda N; Hayashi N; Sagara Y; Hara F; Kadoya T; Matsui A; Miyazaki C; Shien T; Tokunaga E; Hayashi T; Niikura N; Maeda S; Komoike Y; Bando H; Kanbayashi C; Iwata H
Breast Cancer; 2021 Jul; 28(4):896-903. PubMed ID: 33599914
[TBL] [Abstract][Full Text] [Related]
18. Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype.
Neagu AN; Whitham D; Seymour L; Haaker N; Pelkey I; Darie CC
Proteomes; 2023 Apr; 11(2):. PubMed ID: 37092454
[TBL] [Abstract][Full Text] [Related]
19. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
20. Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches.
More TH; Taware R; Taunk K; Chanukuppa V; Naik V; Mane A; Rapole S
Metabolomics; 2018 Aug; 14(8):107. PubMed ID: 30830381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
